Zim Laboratories Ltd
Zim Laboratories Ltd Live Price Chart
Zim Laboratories Ltd Technicals
| 20 Day | ₹ 72.772 |
| 50 Day | ₹ 72.669 |
| 100 Day | ₹ 74.998 |
| 200 Day | ₹ 80.988 |
| 20 Day | ₹ 73.438 |
| 50 Day | ₹ 72.036 |
| 100 Day | ₹ 72.312 |
| 200 Day | ₹ 83.512 |
Zim Laboratories Ltd Performance
| Previous Close | ₹ 71.65 |
| High | ₹ 71.99 |
| Volume | 20960 |
| 52W Range | ₹ - ₹ |
| Open | ₹ 71.46 |
| Low | ₹ 70.5 |
| Market Cap | ₹ 347 Cr |
Zim Laboratories Ltd Fundamentals
| ROCE | 6.751 |
| P/E Ratio | 47.120 |
| P/B Ratio | 1.390 |
| Industry P/E | 1.390 |
| Debt to Equity | 39.451 |
| ROE | 3.367 |
| EPS | 1.530 |
| Dividend Yield | 0.000 |
| Book Value | 52.022 |
| Face Value | 10.000 |
Zim Laboratories Ltd Financials
| Particulars | Y202503 | Y202403 | Y202303 | Y202203 | Y202103 |
|---|---|---|---|---|---|
| Total Revenue | 381.2564 | 370.1642 | 402.9619 | 333.9999 | 306.0784 |
| Total Expenses | 363.6443 | 347.1245 | 367.0439 | 314.7033 | 292.3175 |
| Profit After Tax | 11.744 | 16.7555 | 25.0088 | 13.0128 | 5.6162 |
Zim Laboratories Ltd Shareholding Pattern
| Promoter Holdings | 33.257 % |
| FIIs | 0.020 % |
| DIIs | 0.204 % |
| MutualFund | 0.000 % |
| Retail | 36.626 % |
| Others - | 29.894 % |
About Zim Laboratories Ltd
History of Zim Laboratories Ltd
Zim Laboratories Limited was incorporated in February, 1984 under the name and style of Zim Laboratories Private Limited in Maharashtra. The Company became a Public Limited Company through fresh Certificate of Incorporation issued by the Registrar of Companies, Mumbai. The Company is engaged in the manufacturing of formulation on drugs and pre formulation ingredients in India and marketing and selling these within and outside India. The Pharma Industry is dominated by Multinationals, Large Indian companies and in the lower end of the market large number of units mainly in the SSI sector. During the year 2019-20, ZIM Health Technologies Limited was acquired, making it a wholly owned subsidiary of the Company. SIA ZIM Laboratories Limited got incorporated as a wholly owned subsidiary in Latvia. In 2023, the Company launched Thinoral (Patented Oral Thin Film technology) as an alternate drug delivery platform across RoW/ Pharmerging Markets and EU. The Company entered into a joint venture with an Australian marketing company to launch New Innovative Products (NIP) and Oral Thin Films (OTF) in 2025. The OTF business marked a milestone with its first commercial order supplied in Europe for Sildenafil citrate 50 milligram ODS. The product was launched in Italy and Malta in 2025. ...
